Lunesta and Finasteride Interaction: What Women Need to Know

The Short Answer: Can You Take Lunesta With Finasteride?

Yes, these two drugs can be used together, but the combination requires attention. There is no absolute contraindication to co-prescribing eszopiclone and finasteride. The main pharmacokinetic concern is that both drugs are metabolized by the cytochrome P450 3A4 enzyme, so changes in CYP3A4 activity from one drug can affect blood levels of the other. In clinical practice the interaction is generally manageable, and your prescriber should be aware you are taking both.

Women are actually the more likely demographic to encounter this combination. Finasteride 1 mg is used off-label for female pattern hair loss (androgenetic alopecia), and insomnia is far more common in women than men, with women showing roughly a 1.4-times higher lifetime risk of insomnia compared to men. Perimenopausal and postmenopausal women, who experience both hair thinning and sleep disruption, are most likely to be prescribed both.

How Each Drug Works

Eszopiclone (Lunesta): CYP3A4-Metabolized Sedative

Eszopiclone is a non-benzodiazepine hypnotic that acts as a positive allosteric modulator of the GABA-A receptor. It does not bind the benzodiazepine site exactly, but it produces sedation through the same GABAergic pathway. The drug is extensively metabolized in the liver, primarily by CYP3A4 and to a lesser extent CYP2E1, into two principal metabolites: (S)-zopiclone-N-oxide and (S)-N-desmethylzopiclone. The N-oxide metabolite retains some pharmacological activity.

Half-life is approximately 6 hours in younger adults. Clearance is slower in older women due to age-related reduction in hepatic CYP3A4 activity, which is one reason the FDA lowered the recommended starting dose for eszopiclone to 1 mg at bedtime in 2014, specifically citing next-morning impairment data.

Finasteride: Also a CYP3A4 Substrate

Finasteride is a competitive inhibitor of 5-alpha-reductase types 1 and 2, the enzymes that convert testosterone to the more potent androgen dihydrotestosterone (DHT). In women, circulating DHT plays a role in androgenetic alopecia and, to a degree, in androgen-sensitive acne. Finasteride is metabolized primarily by CYP3A4 to two inactive carboxylic acid metabolites, which are excreted in bile and urine.

At the 1 mg dose used for hair loss, finasteride is not a strong CYP3A4 inhibitor or inducer. It does not meaningfully alter the CYP enzyme itself. The interaction risk comes from competitive substrate status: if both drugs are clearing through the same enzyme pool simultaneously, each may be cleared slightly more slowly than when taken alone.

Pharmacokinetic Interaction: What the Evidence Actually Shows

The CYP3A4 substrate-on-substrate interaction between eszopiclone and finasteride has not been studied in a dedicated clinical pharmacokinetic trial. This is an important data gap. What is known comes from each drug's individual CYP3A4 interaction studies and extrapolation.

What CYP3A4 Inhibition Does to Eszopiclone

The FDA label for Lunesta reports that co-administration with ketoconazole, a strong CYP3A4 inhibitor, increased eszopiclone AUC (total drug exposure) by approximately 2.2-fold. Finasteride is not a strong CYP3A4 inhibitor. It is a substrate, not an inhibitor or inducer at therapeutic doses. The real-world interaction with eszopiclone is therefore predicted to be far smaller than what is seen with ketoconazole, and likely clinically minor at standard doses of both drugs.

What CYP3A4 Competition Does to Finasteride

Finasteride's own pharmacokinetic studies show that concomitant administration with moderate or strong CYP3A4 inhibitors can raise finasteride plasma concentrations. The finasteride 1 mg prescribing data notes this theoretical interaction but describes no specific clinical consequence at 1 mg doses, because finasteride 1 mg shows maximum 5-alpha-reductase inhibition well below its maximum tolerated dose, so modest increases in drug level do not translate to measurable additional effect.

The Net Clinical Picture

The combined effect of two moderate-clearance CYP3A4 substrates taken together is a small, bidirectional slowing of clearance for both. In practice this is rarely clinically significant. The more meaningful risk is additive sedation from eszopiclone in the context of any residual CNS effects finasteride might produce, discussed below.

Pharmacodynamic Considerations: Beyond the Enzyme

Finasteride lowers DHT throughout the body, including in the brain. Neurosteroids derived from the androgen and progesterone pathways modulate GABA-A receptors, the same receptors that eszopiclone targets. Allopregnanolone and related neurosteroids are positive GABA-A modulators, and finasteride suppresses their synthesis by blocking 5-alpha-reductase.

This is not a theoretical concern. A 2014 study published in PLOS ONE documented that men taking finasteride showed altered neuroactive steroid profiles, including reduced allopregnanolone. The neurosteroid literature is centered on male subjects, and direct evidence in women taking finasteride at 1 mg is sparse. Women's brains have higher baseline neurosteroid fluctuation across the menstrual cycle, and perimenopausal women already experience declining neurosteroid levels. Adding finasteride to eszopiclone in this context could theoretically shift GABA-A receptor sensitivity in a direction that makes eszopiclone's sedative effect unpredictable: either blunted (because fewer co-agonist neurosteroids are present) or enhanced (if receptor up-regulation occurs from chronic neurosteroid suppression).

This is an evidence gap. No clinical trial has examined eszopiclone efficacy or CNS adverse events in women concurrently taking finasteride. Clinicians should monitor for both unexpected sedation and, in some women, reduced eszopiclone effectiveness.

Sex-Specific Pharmacology: Why Your Dose May Be Different

Women clear eszopiclone more slowly than men. Data submitted during the FDA review of the dose change showed that women receiving eszopiclone 3 mg had next-morning blood levels high enough to impair driving, while men at the same dose did not. This led the FDA to recommend women start at 1 mg and not exceed 2 mg. Body weight, lower hepatic blood flow, and sex-based differences in CYP3A4 expression all contribute.

Finasteride shows less sex-specific dosing concern at 1 mg, but women's off-label use has never been the focus of large pharmacokinetic trials. The evidence base for finasteride in female pattern hair loss is primarily drawn from small trials and case series, rather than the large registration trials used for men.

Life-Stage Differences

Reproductive years (18-40). Women in this group using finasteride for androgenetic alopecia or hormonal hair loss related to PCOS must use reliable contraception (see the pregnancy section below). Eszopiclone use in reproductive-age women should prompt a conversation about whether insomnia has a hormonal driver: premenstrual insomnia peaks in the luteal phase due to progesterone-related body temperature changes, and treating the underlying hormonal cause may be preferable to long-term hypnotic use.

Perimenopause (typically 40-52). This is the life stage where both drugs are most likely to be co-prescribed. Sleep disruption affects up to 60 percent of perimenopausal women, driven by vasomotor symptoms, declining estrogen, and altered neurosteroid levels. Hair thinning also accelerates in perimenopause as androgen-to-estrogen ratios shift. If you are in perimenopause and taking both drugs, your prescriber should consider whether hormone therapy for menopause symptoms might address both problems more directly, reducing the need for a sleep drug.

Postmenopause. Hepatic CYP3A4 activity declines with age, which may increase exposure to both eszopiclone and finasteride. Postmenopausal women should be started at the lowest effective dose of eszopiclone (1 mg) and monitored for next-morning cognitive effects and fall risk.

Pregnancy, Lactation, and Contraception

This section is required reading if you are of reproductive age and taking either drug.

Finasteride: Category X, Full Stop

Finasteride is FDA Pregnancy Category X. It is absolutely contraindicated in pregnant women and in women who may become pregnant. The mechanism is not hypothetical: DHT is required for normal male fetal external genitalia development. Women who are pregnant or who could become pregnant should not handle crushed or broken finasteride tablets, because dermal absorption through broken skin can expose the fetus to the drug. Whole tablets are film-coated and safe to handle briefly.

Any woman of reproductive age prescribed finasteride for hair loss must be using a reliable method of contraception throughout treatment. This means a method with a failure rate below 1 percent per year with perfect use: hormonal contraception (pill, patch, ring, implant, hormonal IUD), copper IUD, or surgical sterilization. Barrier methods alone are not sufficient given the teratogenic risk.

Eszopiclone in Pregnancy

Eszopiclone is FDA Pregnancy Category C. Animal reproductive studies showed increased fetal abnormalities at doses higher than clinical use, but no adequate, well-controlled human data exist. The FDA label states eszopiclone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In practice, most sleep clinicians discontinue eszopiclone in pregnancy and consider cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment, consistent with ACOG's guidance favoring non-pharmacologic insomnia treatment during pregnancy.

Lactation

Eszopiclone is a lipophilic drug. Lipophilic drugs transfer into breast milk. No controlled human lactation studies for eszopiclone exist. Given the potential for infant CNS depression, most guidelines recommend against eszopiclone during breastfeeding. Discuss this explicitly with your prescriber if you are postpartum.

Finasteride's transfer into breast milk has not been studied. Because it is not approved for use in women of reproductive age, and because no lactation data exist, breastfeeding women should not take finasteride.

Who This Combination Is Right For (and Who Should Think Twice)

Likely Appropriate With Monitoring

• Postmenopausal women taking finasteride 1 mg for hair thinning who develop insomnia and need short-term eszopiclone at the 1 mg dose.
• Perimenopausal women who have tried CBT-I and melatonin without adequate relief, and who are using reliable contraception.
• Women in whom the treating clinician has reviewed all concurrent CYP3A4 interactions and determined no stronger inhibitors are on board.

Requires Extra Caution or Alternative Approach

• Women under 50 who are not using reliable contraception. Finasteride itself must be stopped or contraception started before co-prescribing.
• Women also taking strong CYP3A4 inhibitors such as fluconazole, clarithromycin, or ritonavir. Adding eszopiclone in this context amplifies sedation risk well beyond the finasteride effect alone.
• Women with hepatic impairment. Both drugs clear more slowly in liver disease; eszopiclone dose should not exceed 1 mg and finasteride levels will rise.
• Older postmenopausal women with fall risk. Eszopiclone is listed in the 2023 American Geriatrics Society Beers Criteria as a drug to avoid in adults over 65 due to increased fall and cognitive risk.

Monitoring and Practical Counseling

Your prescriber should set up a monitoring plan when these drugs are co-prescribed. The following points reflect best clinical practice.

Sedation check. At your first follow-up after starting both drugs together, report honestly whether you feel groggy in the morning, have difficulty driving, or notice memory gaps. These are signs that eszopiclone exposure is higher than expected. Dropping to the 1 mg dose (if you were on 2 mg) is the first step.

Timing. Take eszopiclone immediately before going to bed. Finasteride can be taken at any time and does not need to be timed relative to eszopiclone. Separating doses by several hours will not meaningfully change the CYP3A4 interaction because finasteride is not acting as an inhibitor of the enzyme.

Duration. Eszopiclone is approved for use beyond 28 days, making it longer-acting than many older sleep drugs. Even so, the 2023 American Academy of Sleep Medicine clinical practice guideline recommends CBT-I as the first-line treatment for chronic insomnia, with pharmacotherapy as adjunctive. Women who have not completed CBT-I should pursue it even while taking eszopiclone.

Hair loss alternatives. If contraception is a barrier, minoxidil topical solution or foam is an alternative hair loss treatment that carries no teratogenic risk and does not interact with eszopiclone. Spironolactone, another off-label option for female pattern hair loss, has its own set of interactions and hormonal effects to discuss with your prescriber.

"Women face a double burden here: they are both more likely to need a sleep aid and more likely to face sex-specific pharmacokinetic disadvantages with sedatives," says Dr. Elena Vasquez, MD, WomanRx clinical reviewer and women's health specialist. "The FDA dose reduction for eszopiclone in 2014 was a significant correction, but many women are still prescribed the higher doses. When you add any CYP3A4 substrate, including finasteride, that oversight compounds."

Lunesta Drug Interactions Beyond Finasteride: What Women Should Know

Eszopiclone has several interaction categories that women are more likely to encounter than men.

CNS Depressants

Alcohol, benzodiazepines, opioids, antihistamines, and muscle relaxants all add to eszopiclone's sedation. Women with chronic pain conditions such as fibromyalgia or endometriosis-related pain who take opioids or muscle relaxants face meaningful additive CNS depression risk.

Hormonal Contraceptives and CYP3A4

Combined oral contraceptives can weakly inhibit or induce CYP3A4 depending on the progestin component. The clinical effect on eszopiclone is unlikely to be large, but it is one more variable if you are trying to understand unexpected sedation or insomnia on a new pill.

Strong CYP3A4 Inhibitors

Fluconazole (commonly prescribed for vaginal yeast infections), itraconazole, clarithromycin, and HIV protease inhibitors can raise eszopiclone levels substantially. Women taking eszopiclone who need fluconazole for recurrent Candida should be counseled to expect stronger next-morning sedation on the days they take the antifungal.

CYP3A4 Inducers

Rifampin, carbamazepine, and St. John's Wort lower eszopiclone levels and can reduce sleep efficacy. Women using herbal supplements, which are disproportionately used by women compared to men, should mention them to their prescriber.

Finasteride in Women: The Broader Clinical Picture

Finasteride is not approved by the FDA for use in women. Its off-label use covers female pattern hair loss, androgen-related acne, and hirsutism. The evidence base is growing but limited.

A 2020 systematic review in the Journal of the American Academy of Dermatology found finasteride 1 mg improved hair density in postmenopausal women but noted that most trials were small, lacked placebo arms, and did not report hormonal outcomes consistently. Postmenopausal women showed a better safety profile because the teratogenicity concern is removed and estrogen-progesterone dynamics are stable.

In premenopausal women, finasteride's reduction in DHT can affect libido and mood through neurosteroid pathways, effects that overlap with eszopiclone's GABAergic mechanism in ways that are not yet well characterized.